

Pathogenesis of Paget's disease of bone

Noriyoshi Kurihara¹
G. David Roodman^{1,2}

¹ University of Pittsburgh, Medicine/Hematology-Oncology
² VA Pittsburgh Medical Center, Medicine/Hematology-Oncology, Pittsburgh, PA, USA

Address for correspondence:
G. David Roodman, M.D., Ph.D.
Professor of Medicine, University of Pittsburgh
VA Pittsburgh Healthcare System (646),
Medicine/Hematology-Oncology (111-H),
University Drive, Pittsburgh, PA 15240, USA
Ph. +1 412 688 6571
Fax +1 412 688 6960
E-mail: roodmangd@upmc.edu

Summary

Paget's disease (PD) is the most flagrant example of disordered bone remodeling, with abnormalities in all phases of the bone remodeling process. Although the basis for the abnormal osteoclast (OCL) activity in PD is still unclear, several pathophysiologic features of PD and pagetic OCL have been demonstrated. These include: 1) pagetic OCL precursors and OCL express the measles virus nucleocapsid protein (MVNP) gene, suggesting a possible viral etiology for PD; 2) pagetic OCL express increased levels of the *TRAF7* gene; 3) pagetic OCL precursors are hyperresponsive to $1,25\text{-(OH)}_2\text{D}_3$ and RANKL, and they can form OCL at very low concentrations of either ligand; 4) pagetic OCL has an increased rate of formation, increased nuclear number and bone resorbing capacity; and 5) a genetic component is involved in PD. Recently, mutations in the *po2* gene (sequestasome-1) have been linked to PD in a third of patients with familial PD and about 10% of patients with sporadic PD. Currently, it is unknown if both the genetic and viral components are required for the development of PD. However, it is clear that *MVNP* gene expression in pagetic OCL precursors results in development of the pagetic phenotype in OCL. The genetic component appears to increase basal osteoclastogenesis but by itself may not be sufficient to induce PD.

KEY WORDS: osteoclast, Paget's disease, measles virus, sequestasome.

Introduction

Paget's disease (PD) of bone was first described in 1876 by James Paget as a disease that begins at middle-age or later and affects the long bones of the lower extremities, the pelvis and the skull. The bones enlarge and soften, and those bearing weight yield and become unnaturally curved or misshapen (1). This description remains accurate, although not all patients experience bone deformities. A recent study estimates that up to 70% of patients may be asymptomatic (2). Bone pain is the most common complication. Other symptoms may include deafness, nerve compression syndrome and pathological frac-

tures (3). The most devastating complication of PD is osteoclastoma, which is a very rare complication of the disease and occurs in less than 1% of patients. However, the vast majority of osteosarcomas in adults occur in patients with PD.

PD is particularly prevalent in populations of Northern European ancestry. Recently, the prevalence of the disease in the United States has been estimated to be approximately 1.3% in the population over the age of 55, which is a decrease from 5.4%, estimated in the 1970s (2). A similar decline in disease prevalence has also been reported in New Zealand (4). A current prevalence of 2% has been estimated in the United Kingdom (5). The prevalence of PD increases with age, such that the prevalence in the population over the age of 85 is almost 5 times that of the population under the age of 60. Differences in disease incidence is found at different geographic locations with a particular hot spot in the Lancashire region in the United Kingdom. PD is the second most common bone disease in the population over the age of 55 in the United States, the United Kingdom, and in other Caucasian populations.

PD is primarily a disease of osteoclasts (OCL) with abnormal function. This in turn leads to excessive osteoblast activity and is reflected in serum alkaline phosphatase, which is elevated in 85% of patients. Bisphosphonates, by inactivating OCL, in turn normalize the osteoblast activity, indicated by a reduction in serum alkaline phosphatase. X-rays and isotope bone scans are used to identify affected skeletal sites. PD can affect one or multiple bones, and is highly localized. The disease can spread within a particular site, but it rarely spreads to new sites. This feature distinguishes PD from three more progressive diseases with similar bone histology: Familial Expansile Osteolysis (FEO), Expansile Skeletal Hyperphosphatasia (ESH), and Juvenile Paget's Disease (JPD).

Bone histology and OCL phenotype in PD

Typical features of bones involved with PD include excessive numbers of OCL, which in turn are increased in size and nuclear number per OCL (Figure 1), large numbers of highly active osteoblasts, the presence of woven bone and often a highly cellular bone marrow.

Pagetic OCL have been extensively investigated by TEM and immunohistochemistry (Figure 2) ever since they were first reported to contain intranuclear, or less frequently, intracytoplasmic inclusions. Intranuclear inclusions are found in almost all cases of PD (6) and the perceived similarity of these structures to paramyxovirus nucleocapsids (7) has led to the hypothesis that PD may be caused by a persistent infection by measles virus (MV) or another paramyxovirus (8, 9). This issue remains unresolved as evidence for or against the role of paramyxoviruses in the etiology of this disease has been presented over many years (10,11). The inability of various groups working in this field to confirm each other's findings has continued the discussion.

Reddy et al. reported the presence of measles virus nucleocapsid sequences in patients with PD, which can be amplified from bone marrow, blood cells, and early hematopoietic colony-forming cells in the United States (12). Recently, the




Figure 1 - Osteoclasts in Paget's disease. Pagetic osteoclasts are increased in both number and size and contain increased nuclei per multinucleated cells. In addition, these cells show an increased bone resorbing capacity.



Figure 2 - Transmission Electron Microscopy (TEM) and immunocytochemistry of osteoclasts from patients with Paget's disease. A viral etiology has been suggested for Paget's disease. Paramyxoviral-like nuclear and cytoplasmic inclusions are present in osteoclasts from the majority of patients (A). Immunocytochemical studies have shown that pagetic osteoclasts express measles virus and respiratory syncytial virus nucleocapsid antigens (B).

amplification of a complete measles coding sequence has been reported (13). Contrary to these results, Mee et al. had reported the presence of canine distemper virus, but not measles virus (14). However, others were unable to detect any paramyxovirus in Paget's patients (15). No intact virus has ever been recovered from a patient with PD. Not only has the presence of viral nucleic acids in pagetic tissue been questioned, but the whole basis for considering paramyxovirus in the etiology of the disease (15), since the intranuclear inclusions in PD are ultrastructurally dissimilar to these seen in subacute scler-

osing panencephalitis (SSPE), the only known persistent measles infection (11).

In support of the role for a virus in the etiology of PD, however, are our studies indicating that measles virus infection of murine OCL, made susceptible by transfection with the human measles virus receptor (CD46), resulted in pagetic features in OCL, specifically enhanced nuclearity (16). The final analysis of a viral involvement in PD must await the elucidation of the undisputed genetic component in this disease (17). Only once the predisposing/causative genes have been identified will it be possible to assess whether viral infection is required for expression of the full phenotypic features of the disease.

In vitro study of pagetic OCL

Bone marrow culture techniques that allow the formation of OCLs *in vitro* have provided new insights into the potential pathogenesis of PD. Our laboratory was the first to examine OCL formation from bone marrow obtained from involved bones from patients with PD (18, 20). *In vitro*, increased numbers of OCLs are formed by pagetic precursors, and OCL are larger and contain more nuclei than in controls.

We found that multinucleated cells that formed in marrow cultures from Paget's patients shared many of the characteristics of pagetic OCLs. The OCLs were increased in number (10- to 100-fold) compared to normal marrow cultures, had increased numbers of nuclei per multinucleated cell (up to 100 nuclei per cell as compared to 3-10 nuclei in normal OCL), and expressed high levels of tartrate-resistant acid phosphatase (TRAP). This appears to be caused by the fact that the precursors are hyper-responsive to $1,25\text{-(OH)}_2\text{D}_3$ and RANKL (18-21), rather than through an increase in the number of OCL precursors.

In immunocytochemical studies confirmed that MV and respiratory syncytial virus nucleocapsid antigens were expressed in OCLs formed *in vitro* in these cultures (22). OCL formation was induced by concentrations of $1,25\text{(OH)}_2\text{D}_3$ that were 1 to 2 logs lower than that required for OCL formation in normal marrow cultures, suggesting that OCL precursors from Paget's patients were hyper-responsive to $1,25\text{(OH)}_2\text{D}_3$ (20). In support of this finding, Kurihara et al. have shown that transduction of normal OCL precursors, CFU-GM, with retroviral constructs containing the cDNA for the *MVNP* gene, induce OCL precursors to form OCL that express a pagetic phenotype and are hyper-responsive to $1,25\text{(OH)}_2\text{D}_3$ (23). They have further shown that using GST-VDR chimeric protein pull-down assays with lysates from *MVNP* transduced normal OCL precursors and marrow cells from involved bones from patients with PD, that a potential coactivator of VDR, TAF_{II}-17 (24), which is not expressed in normal OCL precursors, is overexpressed in pagetic OCL and may be playing a role in the hyper-responsivity to $1,25\text{(OH)}_2\text{D}_3$ (25). The molecular basis for the increased affinity of $1,25\text{(OH)}_2\text{D}_3$ for the VDR appears to result from enhanced expression of co-activators that interact with VDR, in particular TAF_{II}-17, a member of the TF_{II}D transcription complex (24, 25). Menna et al. had also shown that OCL precursors from patients with PD are also hyper-responsive to RANK ligand (26).

VDR coactivator expression in PD

As noted above, one of the earliest findings from *in vitro* studies of PD is that pagetic OCL precursors are hyper-responsive to $1,25\text{(OH)}_2\text{D}_3$ and form OCL at concentrations of $1,25\text{(OH)}_2\text{D}_3$ that are physiologic rather than pharmacologic. The increased responsiveness to $1,25\text{(OH)}_2\text{D}_3$ is not due to increased levels of the Vitamin D receptor (VDR) nor to increased affinity

of 1,25-(OH)₂D₃ for VDR. Kurihara et al. had shown by using GST-VDR chimeric protein pull-down assays that TAF_{II}-17, a member of the TF_{II}D transcription complex, is increased in OCL precursors from patients with PD compared to normals. Kurihara et al. further showed that TAF_{II}-17 could enhance VDR mediated gene transcription and allow formation of the transcription complex at very low levels of 1,25-(OH)₂D₃. In addition, other coactivators of VDR, including CPB/p300 and DRIP205, are also increased in OCL precursors from Paget's patients (27). These data suggest that the enhanced sensitivity of OCL precursors to 1,25-(OH)₂D₃ in PD results from increased expression of coactivators of VDR.

Expression of the pagetic phenotype in OCL requires VDR dependent gene transcription

Transduction of normal CFU-GM with retroviral constructs containing the cDNA for the measles virus nucleocapsid (MVNP) gene can induce these cells to form OCL that express a pagetic phenotype and are hyper-responsive to 1,25-(OH)₂D₃. This result suggested that VDR plays a key role in the abnormal OCL activity in PD. Therefore, to test this hypothesis, OCL precursors from VDR^{-/-} and VDR^{+/+} mice were transfected with the MVNP gene, and the characteristics of OCL formed examined. PCR analysis of MVNP transduced VDR^{-/-} and VDR^{+/+} OCL precursors demonstrated that both cell types expressed high levels of TAF_{II}-17. OCL formation was significantly decreased in bone marrow cultures from VDR^{-/-} mice treated with RANKL compared to marrow cultures from VDR^{+/+} mice. Furthermore, the OCL that formed in marrow cultures of VDR^{-/-} mouse transfected with the MVNP gene did not express a pagetic phenotype. In contrast, MVNP transfected VDR^{+/+} mouse cells treated with RANKL formed large numbers of abnormal OCL that expressed a pagetic phenotype. As expected, VDR^{-/-} marrow cells did not form OCL in response to 1,25-(OH)₂D₃. These data suggest that VDR mediated gene transcription may be required for expression of a pagetic phenotype in OCL.

Genetics of PD

PD is a complex disease where multiple genetic factors have been identified. A genetic component appears to be involved in PD, with at least six loci now linked to PD.

The genetic basis for PD stems from the observation that familial clustering is common and that ethnic differences in prevalence persist after migration. Between 15-40% of patients have an affected first-degree relative, and first-degree relatives have a seven-fold increased risk of developing the disease compared to controls (28). Familial PD has an autosomal dominant mode of inheritance with high penetrance. Linkage analysis in families initially concentrated on HLA alleles and a susceptibility locus was described on chromosome 6q21 (29).

However, further studies, including genome wide searches, have failed to confirm this region as important in PD (30,31). Following the cloning of RANK and the realization that RANK is critical for OCL differentiation (32) led to the examination of chromosome 18 in PD, RANK maps to critical region on chromosome 18q, previously linked to FEO, a more severe disease with clinical and histological similarities to PD. Linkage studies also explored the involvement of 18q21-22 and mutations in RANK in PD. Linkage to 18q21-22 was found in a number of families (33,34), however, only one Japanese family with severe, early onset PD was found to have a mutation in RANK (35). It is now well-established that PD is rarely linked to 18q21-22 (36) and mutations in RANK and OPG genes do not

give rise to adult PD (37), but rather, to more severe, early onset disorders.

Having found a link of PD to chromosome 5q in a number of French-Canadian families, Laurin et al. (38) recently described a non-conservative heterozygous point mutation in a novel gene, sequestosome 1 (SQSTM1) in 11% of familial and 16% of sporadic PD (38). Mutations in p62 are the most frequently reported genetic mutations and affects about 26% of patients with familial PD and 9% of sporadic cases (39). More recently, the identification of new mutations in SQSTM1 have been reported in the Netherlands (40) and Belgian patients with PD (41).

In the familial PD, the mutations co-segregated with the disease but were seen in small numbers of unaffected family members but not in a large number of non-pagetic controls. These data indicated that these mutations may not by themselves be sufficient to cause PD. SQSTM1 codes for p62, a widely expressed ubiquitin-binding protein (41), which acts as a scaffold protein in the NF- κ B signaling pathway, facilitating TNF- α , CD40 and IL-1 through its interactions with the atypical protein kinases, PKC δ or PKC ζ (42-44).

The mutations found in PD so far are all predicted to affect the ubiquitin-binding domain of the protein and to abolish or reduce ubiquitin binding. The P392L mutation is the most frequent mutation reported. The biological consequences of p62 remain to be substantiated in transgenic mice and knockout mice (45) and further *in vitro* experiments. Whereas ubiquitinated proteins, destined for degradation in the proteasome, generally bind ubiquitin in a covalent manner on single residues, p62 appears to use a large domain to bind ubiquitin in a non covalent manner. Given this difference, it is unclear whether ubiquitin binding by p62 leads to its own degradation, or whether instead it has a role to play in regulating ubiquitination of other signaling molecules by controlling intracellular availability of ubiquitin. Further cell biological experiments are required to elucidate the role of p62 and its specific importance in OCL formation. Recently, we have targeted p62 (P392L) to the OCL lineage in transgenic mice. These mice show increased OCL formation and activity but do not develop PD by age 4 months.

The genetics of PD is under intense investigation and the other genes mutated in PD will, no doubt, soon be found in the remaining susceptibility loci. Only once all the genes involved in this heterogeneous disorder have been identified will it be possible to examine fully the etiology and biology of the disease. Transgenic mice, harboring the various mutations found in patients, may be useful as models, but may not develop the disease unless exposed to appropriate environmental triggers, for example, viral infection, ageing or fracture. Such studies will be complex, but may provide the only tool to help dissect their contribution to disease development. In addition, such studies will help to provide a better understanding of the unique role of the primary genes affected in the biology of the OCL.

Conclusion

PD appears to require both a genetic and environmental factor. VDR mediated gene transcription is required for expression of a pagetic phenotype in OCL, and the p62_{MUT} causes increased NF- κ B signaling and OCL formation in response to RANKL and TNF- α . MVNP increases 1,25-(OH)₂D₃ responsivity and induces TAF_{II}-17. These data suggest that p62_{MUT} increases basal OCL formation in PD patients but is not sufficient to induce the complete PD phenotype in OCL precursors without an environmental component that affects VDR mediated gene transcription.

References

1. Paget J. On a form of chronic inflammation of bones (Osteitis Deformans). *Med-Chir Trans.* 1876;37-63.
2. Tieggs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget's disease of bone. *Bone.* 2000;27:423-427.
3. Selby P, Davie M, Ralston S, Stone M. Guidelines on the management of Paget's disease of bone. *Bone.* 2002;31:366-373.
4. Cundy T, Wattie D, Busch S, Rutland M, Ibbertson HK. Paget's disease in New Zealand: is it changing? *Bone.* 1999;24:7S-9S.
5. Cooper C, Shafheutle K, Dennison K, Guyer P, Barker DJ. The epidemiology of Paget's Disease in Britain: Is the prevalence decreasing? *J Bone Miner Res.* 1999;14:192-197.
6. Harvey L, Gray T, Beneton MNC, Douglas DL, Kanis JA, Russell RGG. Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral etiology. *J Clin Pathol.* 1982; 35:771-779.
7. Mills BG, Singer FR. Nuclear inclusions in Paget's disease of bone. *Science.* 1976;194:201-202.
8. Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. *Clin Orthop Rel Res.* 1984;183:303-311.
9. Rebel A, Basle M, Pouplard A, Malkani K, Filmon R, Lepatezour A. Bone tissue in Paget's disease of bone. Ultrastructure and immunocytochemistry. *Arth Rheum.* 1980;23:1104-1114.
10. Ralston SH, Helfrich MH, Hobson RP, Pennington TH. Does Paget's disease really have a viral etiology? *J Bone Miner Res.* 1997;12:863-864.
11. Rima BK. Paramyxoviruses and chronic human diseases. *Bone.* 1999;24:23S-26S.
12. Reddy SV, Mena C, Singer FR, Cundy T, Cornish J, Whyte MP, Roodman GD. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. *Exp Hematol.* 1999;27:15:8-15:32.
13. Friedrichs WE, Reddy SV, Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. *J Bone Miner Res.* 2002;17:145-151.
14. Mena C, Dixon SA, Hoyland JA, Davies M, Selby PL, Mawer EB. Detection of Canine Distemper Virus in 100% of Paget's disease samples by in situ-reverse transcriptase polymerase chain reaction. *Bone.* 1997;23:171-175.
15. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Nicholson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. *J Bone Miner Res.* 2000;15:2315-2329.
16. Reddy SV, Kurihara N, Mena C, Landucci G, Forthal D, Koop BA, Windle JJ, Roodman GD. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. *Endocrinology.* 2001;142:2898-2905.
17. Leach RJ, Singer FR, Roodman GD. The genetics of Paget's disease of the bone. *J Clin Endocrinol Metab.* 2001;86:24-28.
18. Kukita A, Chenu C, McManus LM, Mundy GR, Roodman GD. Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. *J Clin Invest.* 1990;85:1280-1286.
19. Flanagan AM, Horton MA, Dorey EL, Collins DA, Evely RS, Moseley JM, Firkin FC, Chambers TJ, Helfrich MH, Martin TJ. An assessment of the ability of human bone marrow cultures to generate osteoclasts. *Int J Exp Pathol.* 1992;73:387-401.
20. Mena C, Barsony J, Reddy SV, Cornish J, Cundy T, Roodman GD. 1,25-Dihydroxyvitamin D₃ hypersensitivity of osteoclast precursors from patients with Paget's disease. *J Bone Miner Res.* 2000;15:228-236.
21. Neale SD, Smith R, Wass JA, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D₃ and RANKL. *Bone.* 2000;27:409-416.
22. Mills BG, Frausto A, Singer FR, Ohsaki Y, Demulder A, Roodman GD. Multinucleated cells formed in vitro from Paget's bone marrow express viral antigens. *Bone.* 1994;15:443-448.
23. Kurihara N, Reddy SV, Araki N, Ishizuka S, Ozono K, Cornish J, Cundy T, Singer FR, Roodman GD. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease. *J Bone Miner Res.* 2004;19:1154-64.
24. Mengus G, May M, Jacq X, Staub A, Tora L, Chambon P, Davidson I. Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID. *EMBO J.* 1995;14:1520-1531.
25. Hoffmann A, Roeder RG. Cloning and characterization of human TAF20/15. Multiple interactions suggest a central role in TFIID complex formation. *J Biol Chem.* 1996;271:18194-18202.
26. Kurihara N, Ishizuka S, Demulder A, Mena C, Roodman GD. Paget's disease-a VDR coactivator disease? *J Steroid Biochem Mol Biol.* 2004;89-90:321-325.
27. Mena C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, Cornish J, Singer FR, Bruder JM, Roodman GD. Enhanced RANK ligand expression and responsiveness of bone marrow cells in Paget's disease of bone. *J Clin Invest.* 2000;105:1833-1838.
28. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. *J Bone Miner Res.* 1991;6:495-500.
29. Tilyard MW, Gardner RJ, Milligan L, Cleary TA, Stewart RD. A probable linkage between familial Paget's disease and the HLA loci. *Aust NZ J Med.* 1982;12:498-500.
30. Hocking LJ, Herbert CA, Nicholls RK, Williams F, Bennett ST, Cundy T, Nicholson GC, Wuyts W, Van Hul W, Ralston SH. Genome wide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2, 6, 10p12, and 15q15. *Am J Hum Genet.* 2001;69:1055-1061.
31. Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacouciere Y, Drapeau G, Verreault J, Raymond V, Morissette J. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. *Am J Hum Genet.* 2001;69:528-543.
32. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert LA. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature.* 1997;390:175-179.
33. Cody JD, Singer FR, Roodman GD, Otterund B, Lewis TB, Lepert M, Leach RJ. Genetic linkage of Paget disease of the bone to chromosome 18q. *Am J Hum Genet.* 1997;61:1117-1122.
34. Haslam SI, Van Hul W, Morales-Piga A, Balemans W, San-Millan J, Nakatsuka KA, Haites NE, Ralston SH. Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. *J Bone Miner Res.* 1998;13:911-917.
35. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, Van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. *Nat Genet.* 2000;24: 45-48.
36. Hocking L, Slee F, Haslam SI, Cundy T, Nicholson G, Van Hul W, Ralston SH. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. *Bone.* 2000;26:577-580.
37. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, Westhovens R, Verbruggen L, Anderson D, Hughes A, Van Hul W. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. *Bone.* 2001;28:104-107.
38. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. *Am J Hum Genet.* 2002;70:1582-1588.
39. Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, Nicholson GC, Ward L, Bennett ST, Wuyts W, Van Hul W, Ralston SH. Domain-specific mutations in sequestosome 1

- (SQSTM1) cause familial and sporadic Paget's disease. *Hum Mol Genet.* 2002;11:2735-2739.
40. Eekhoff EW, Karperien M, Houtsma D, Zwiderman AH, Dragoescu C, Kneppers AL, Papapoulos SE Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. *Arthritis Rheum.* 2004;50:1650-1654.
 41. Beyens G, Van Hul E, Van Driessche K, Fransen E, Devogelaer JP, Vanhoenacker F, Van Offel J, Verbruggen L, De Clerck L, Westhovens R, Van Hul W. Evaluation of the Role of the SQSTM1 Gene in Sporadic Belgian Patients with Paget's Disease. *Calcif Tissue Int.* 2004;75:144-152.
 42. Vadiamudi RK, Joung I, Strominger JL, Shin J. p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. *J Biol Chem.* 1996; 271:20235-20237.
 43. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. *EMBO J.* 1999;18:3044-3053.
 44. Sanz L, Diaz-Meco MT, Nakano H, Moscat J. The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. *EMBO J.* 2000;19: 1576-1586.
 45. Duran A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J, Diaz-Meco MT. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. *Dev Cell.* 2004;6:303-309.

FOR REVIEW ONLY
© CIC EDIZIONI INTERNAZIONALI